Cannara Reports Q1 Fiscal 2026 Results, Delivers New Record Financial Results, Extends Market Share Gains and Advances Disciplined Expansion Strategy
Cannara Achieves OTCQX Qualification and Announces Release of Fiscal Q1 2026 Financial Results on January 26, 2026
Cannara Achieves #1 Market Share Position in Québec as of December 2025 and Provides Update on Québec Vape Category Launch
Cannara Biotech Delivers Record Fiscal 2025 Revenue and Profitability, Achieves First Year of Positive Retained Earnings
Cannara Biotech Inc. to Announce Fiscal Q4 2025 and Fiscal Year 2025 Financial Results on November 24, 2025 and Provides Board Update
FSD Pharma Generates $7.7 Million in Proceeds and 670 Percent Return on Investment through Sale of Interest in Cannara Biotech
Cannara Biotech Secures $6 Million Mortgage Financing Facility with Canadian Imperial Bank of Commerce
Critical Elements Lithium Corp Announces Investor Relations Partnership With Adelaide Capital and Oak Hill Capital
